Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review by Bougie, O. & Weberpals, J. I.
Hindawi Publishing Corporation
International Journal of Spectroscopy
Volume 2011, Article ID 374012, 11 pages
doi:10.1155/2011/374012
Review Article
Clinical Considerations of BRCA1-a n dBRCA2-Mutation
Carriers: A Review
O.Bougie1 andJ. I. Weberpals2,3
1The Department of Obstetrics, Gynaecology, and Newborn Care, The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6
2Centre for Cancer Therapeutics, Ottawa Hospital Research Institute, The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6
3The Division of Gynaecologic Oncology, The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6
Correspondence should be addressed to J. I. Weberpals, jweberpals@ottawahospital.on.ca
Received 2 April 2011; Accepted 16 June 2011
Academic Editor: Bernardo Garicochea
Copyright © 2011 O. Bougie and J. I. Weberpals. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Individuals who carry an inherited mutation in the breast cancer 1 (BRCA1)andBRCA2genes have a signiﬁcant riskof developing
breast and ovarian cancer over the course of their lifetime. As a result, there are important considerations for the clinician in the
counseling, followup and management of mutation carriers. This review outlines salient aspects in the approach to patients at high
risk of developing breast and ovarian cancer, including criteria for genetic testing, screening guidelines, surgical prophylaxis, and
chemoprevention.
1.Introduction
Research into the hereditary breast and ovarian cancer
genes, breast cancer 1 (BRCA1)a n dBRCA2,i sa na r e ao f
ongoing discovery in the molecular biology of cancer. For
clinicians, it can be an overwhelming challenge to keep a
breast with the latest studies and incorporate the most up-
to-date evidence into their practice. There are many unique
considerations that should be addressed when approaching
patients with a predisposition to hereditary breast and
ovarian cancer, including counseling, screening, and risk-
reducing strategies. It is also important to understand which
high-risk patients should be referred for genetic counseling
for consideration of BRCA1/2 gene testing, an approach
which is often underutilized in physicians’ practices [1]. In
this review, the most relevant and current studies in hered-
itary breast and ovarian cancer epidemiology, screening,
and prevention are outlined to guide the clinician in the
management of high-risk individuals. Also highlighted is the
role of BRCA in sporadic breast and ovarian cancer and the
emergence of novel targeted therapies such as poly(ADP-
ribose) polymerase inhibitors (PARPi) in BRCA1-deﬁcient
patients.
2. Cancer Risk in BRCA1-a n dBRCA2-
Mutation Carriers
In the general population, a woman’s lifetime risk of breast
cancer is 1 in 8 [2], and the risk of ovarian cancer is 1 in 70
[3]. It is estimated that a BRCA1/2 mutation is found in 2–
6% of breast cancer patients [4–6] and 10–15% of epithelial
ovarian cancer patients [7–9]. In all women, the prevalence
of a BRCA1 mutation is 1 in 800 to 1 in 1400 and the
prevalence of BRCA2 mutation is slightly lower at 1 in 450
t o1i n8 0 0[ 6, 10, 11]. The lifetime risk of breast cancer in
BRCA1- and BRCA2-mutation carriers is 45–80% [12, 13].
The lifetime risk of ovarian cancer is 45–60% for BRCA1-
mutation carriers and 11–35% for BRCA2-mutation carriers
[12–14]. A number of studies examining the incidence of
breast cancer have reported a lower likelihood amongst
BRCA2-mutation carriers compared to BRCA1-mutation
carriers [13, 15]. Among the Ashkenazi Jewish population,
the prevalence of a BRCA1/2 mutation is as high as 2.5%
[16]. In breast cancer patients of Jewish origin, the BRCA1
mutation rate is increased at 10% compared to the general
breast cancer population [16]. Even more signiﬁcant, among
Jewishwomanwithovariancancer,thereisanestimated29%
risk of carrying a BRCA1 or BRCA2 mutation [17].2 International Journal of Spectroscopy
Cancerriskhasbeenshowntoincreasesubstantiallywith
eachdecadeoflifeforBRCA1-andBRCA2-mutationcarriers
[12]. A woman with a BRCA mutation has a 20% chance
of developing breast cancer by the time she is 40 years old.
However, the risk increases to 37% by the age of 50, 55% by
the age of 60, and is over 70% by the age of 70. For BRCA1-
mutation carriers, the risk of ovarian cancer rises sharply
in the 4th decade of life and then increases progressively by
approximately 10% with each subsequent decade of life.
Individuals who have a known BRCA mutation are
also at risk for other malignancies. Approximately 30%
of women with fallopian tube cancer have a mutation in
BRCA1 or BRCA2 [18]. In addition, the inheritance of a
BRCA1 mutation has been linked with an increased risk
of endometrial, pancreatic, and prostate cancer [19, 20].
Speciﬁcally, the increased risk of prostate cancer is associated
with the BRCA1 4153delA and the C61G mutations [21].
A BRCA1 mutation has been shown to be associated with
an increased risk of early onset colon cancer in a deﬁned
population but does not seem to increase the overall risk of
colon cancer [22]. Patients with a BRCA2 mutation have an
increased risk of prostate and pancreatic cancer [23–25]. An
earlier study by the Breast Linkage Consortium reported an
increased incidence of gallbladder, bile duct, stomach cancer,
and malignant melanoma in BRCA2-mutation carriers, yet
recent evidence has not substantiated this association [26].
Only the study by Debniak et al. [27] demonstrated that one
common variant of the BRCA2 gene, the N991D variant, is
linked with an increased malignant melanoma risk.
3.Clinicopathologic Featuresof Hereditary
Breast andOvarianCancer
There are several distinguishing clinical and pathologic fea-
tures of breast and ovarian cancer related to BRCA mutation
status. The features of hereditary breast and ovarian cancers
are summarized in Table 1. Compared to nonhereditary
breast cancer patients, BRCA1-mutation carriers are diag-
nosed with breast cancer at a younger age [18, 28], and up
to 80% of cancers occur prior to menopause [18, 29]. At
initial presentation, hereditary breast cancer patients have
a higher incidence of bilateral breast cancer, poorly diﬀer-
entiated tumours, and lymph node positivity [18]. BRCA1-
associated tumours are more often estrogen receptor (ER)
[18],progesterone receptor(PR)[30],and humanepidermal
growth factor 2 (HER2) negative compared to their sporadic
counterparts [31]. BRCA2 tumours, in turn, demonstrate
more ER positivity [18], while the rate of PR and HER2
receptorpositivityissimilartothatofsporadictumours[30].
BRCA1 tumours are more likely to be p53 positive, while
BRCA2 tumours are usually p53 negative [32]. Lee et al.
[33] conducted a recent systemic review to assess the survival
pattern of breast cancer patients with BRCA1 and BRCA2
mutations and found that the BRCA1-mutation carriers
had a signiﬁcantly decreased progression-free as well as
o v e r a l ls u r v i v a lc o m p a r e dt on o n - BRCA1-associated breast
cancerpatients,whileBRCA2mutationscarriershadsurvival
patterns comparable to the general breast cancer patients.
Table 1: Clinicopathologic characteristics of hereditary versus
sporadic breast and ovarian cancer.
Breast cancer Ovarian cancer
Average age of
diagnosis
BRCA1 ↓ BRCA1 ↓
BRCA2 ↔ BRCA2 ↔
Pathological
features
↓ diﬀerentiation ↔ grade, stage
↑ bilateral tumours ? ↑ papillary serous
serology
↑ # lymph nodes
Receptor status
BRCA1: ↑
ER−/PR−/HER2−
BRCA2: similar to
sporadic tumours
Survival
↓ progression
free-survival
↑ progression-free
survival
↓ overall survival ↑ overall survival
There is emerging evidence to suggest that BRCA1-linked
breast cancer patients treated with chemotherapy regimens
containing platinum or doxorubicin and cyclophosphamide
have a high likelihood of achieving pathologic complete
remission [34].
BRCA1-mutation carriers are diagnosed with ovarian
cancer at a younger age (average age 52) compared to
BRCA2-mutation carriers (age 62) and sporadic cases (age
63) [35]. In contrast to breast cancer, BRCA-associated
and sporadic ovarian tumours have been reported to have
similar clinicopathological features (histology, grade, and
stage at diagnosis) [35]. While Boyd et al. [35]f o u n dc o m -
parable ovarian tumour histology between BRCA-associated
and sporadic ovarian tumours, Piek et al. [36]f o u n d
a higher incidence of papillary serous histology among
BRCA-associated ovarian tumours. Patients with BRCA1-o r
BRCA2-linked ovarian cancers were shown to have a longer
disease-free interval following chemotherapy and improved
survival compared to patients with sporadic ovarian cancer
ovarian cancer [35, 37, 38].
4.Pathophysiology ofBRCA-Mutations
BRCA1 and BRCA2 are tumour suppressor genes located
on chromosome 17q21 [39] and 13q12-13 [40], respectively.
Hundreds of diﬀerent mutations can occur within a gene
leading to protein inactivation, with the genetic defect
resulting most commonly in a truncated protein product.
However, a number of missense mutations and large gene
rearrangements can also cause a mutant phenotype [41].
Mutation types tend to correspond with various populations
and ethnicities. For instance, in African Americans, 25%
of BRCA1 mutations were frameshift, 38% missense, 13%
nonsense, and 25% splice mutations, while in non-Hispanic
whitepatients,36%ofBRCA1mutationsareframeshift,14%
are missense, 29% nonsense, and 21% are splice mutations
[5]. In the Ashkenazi Jewish population, there are three
distinct mutations in BRCA1 and BRCA2 genes that are
responsible for the majority of the BRCA mutations seenInternational Journal of Spectroscopy 3
in this population; namely, these are the BRCA1 185delAG,
BRCA1 5382insC, and BRCA2 6174delT mutations [42].
The process of carcinogenesis is often initiated by
repeated episodes of DNA damage, which can occur sec-
ondary to a number of stressors, such as reactive oxygen
species, cytotoxic chemotherapy, and ionizing radiation.
DNA double-strand breaks (DSB) are particularly harmful,
asbothcomplementarystrandsofDNAaredamagedleading
to replication arrest. BRCA1 and BRCA2 play an integral role
in the response to cellular stress, the localization to sites of
damaged DNA, and the activation of DNA repair processes.
Inparticular,BRCA1andBRCA2usuallyrepairDSBthrough
the conservative mechanism of homologous recombination
[43–45]. Central to the process of homologous recombi-
nation, the BRCA proteins bind an essential recombinant,
RAD51, and mutations aﬀecting the binding ability of
BRCA1/2 to RAD51, which lead to genomic instability [45–
47]. While BRCA2 is primarily involved in homologous
recombination repair, BRCA1 is involved in alternate DNA
repair processes such as nonhomologous end joining, which
is error prone [48]. BRCA deﬁciency ultimately leads to the
accumulation of genetic alterations as a result of the failure
of cells to arrest and repair DNA damage or to self-destruct,
resulting in neoplastic progression.
5.GeneticTesting
Identifying patients that should be considered for genetic
testing is an important aspect of practice that is often
overlooked [1]. Pedigree analysis can be used in conjunction
withavailableriskassessmentmodelstodeterminewhethera
family is suspected of having hereditary, familial, or sporadic
cancer [49]. BRCA1 or BRCA2 gene mutations are inherited
in an autosomal dominant fashion. The Manchester scoring
system is a risk assessment model which may be applied to
evaluate an individual’s risk of having a BRCA1 or BRCA2
mutation [50]. The scoring system considers the age of
cancer diagnosis as well as a family history of female breast,
male breast, ovarian, prostate, and pancreatic cancer in the
risk stratiﬁcation model. Recently, breast cancer pathology
has been included in this model to increase predictive
accuracy. It is considered the most sensitive model in
predicting mutations in both BRCA genes [49, 50]. The
disadvantage of the model is that it has been shown to lead
to over-referral for genetic testing.
Speciﬁc criteria for referral for genetic testing vary
amongst institutions but are all based on clinical character-
istics that increase one’s chance of developing a hereditary
breast and/or ovarian cancer. Clinical features that should
prompt one to consider a genetic counseling referral are
outlined in Table 2 [49]. It is important to include genetic
counseling in the cancer risk assessment process [51]. A
number of reports propose criteria for referral for genetic
counseling regarding hereditary risk of breast and/or ovar-
ian cancer, including the National Comprehensive Cancer
Network (NCCN) [52], the U.S. Preventive Services Task
Force (USPSTF) [53], American Congress of Obstetricians
and Gynecologists (ACOG) [54], the National Institute for
Table 2: Clinical features that warrant referral for genetic testing
for BRCA1/2 mutations.
(i) Early-onset breast cancer, usually deﬁned as before age 50 or 45
(ii) Ovarian, fallopian tube or primary peritoneal cancer
(iii) Individuals with two or more primary breast cancers, or breast
and ovarian cancer in the same individual
(iv) Male breast cancer
(v) Two or more individuals in the family with breast and/or
ovarian cancer
(vi) Ashkenazi Jewish ancestry
Health and Clinical Excellence (NICE) [55], and the Euro-
pean Society for Medical Oncology (ESMO) [56]. Guidelines
in most countries use a 10–20% threshold of detecting a
mutation in BRCA1/2 w i t h i nag i v e nf a m i l yb e f o r em u t a -
tional analysis is considered. A recent study analyzed the cost
eﬀectiveness of screening for cancer susceptibility genes and
reported that when one’s risk of having a mutation is at only
10%, genetic screening is not cost eﬀective [57].
6.Surveillance
6.1. Breast Cancer. The NCCN recommends that breast
cancer screening for BRCA1- and BRCA2-mutation carriers
should include annual mammography and clinical breast
examination every 6–12 months, starting at age 25 or
individualized based on one’s family history [52]. In Europe,
ESMO also recommends screening with annual mammogra-
phy and MRI starting at age 25–30 [56]. Ultrasound is gener-
ally not recommended as part of a screening algorithm but is
utilized when mammography or MRI reveals abnormalities.
The addition of ultrasound to screening mammography will
yield an additional 1.1 to 7.2 cancers per 1000 high-risk
women but will also substantially increase the number of
false positive tests [58].
Several studies have conﬁrmed that MRI has a higher
sensitivity for the detection of invasive breast cancer com-
pared to conventional screening [59, 60], and this has
been reported to be most applicable to BRCA1/2-mutation
carriers [59]. Rijnsburger et al. [60] found that 45.8% of
breast cancers in BRCA-mutation carriers and 30.8% of
breast cancers in BRCA2-mutation carriers were detected
onlybyMRI.However,MRIspeciﬁcityforcancerdetectionis
lower than that of conventional screening, thereby resulting
in more unnecessary biopsies [61]. Thus, it may be prudent
to use MRI in conjunction with conventional imaging in
screening women with a high genetic risk of breast cancer.
In the study by Trecate et al. [61], it was advised to consider
ultrasound evaluation when MRI yielded the only positive
diagnostic result.
Lord et al. [62] conducted a systematic review to assess
the eﬀectiveness of adding MRI to mammography with or
without ultrasound and clinical examination in screening
young women at high risk for breast cancer. Consistent
evidence in a number of studies suggests that adding MRI
provides a highly sensitive screening strategy (sensitivity4 International Journal of Spectroscopy
range: 93–100%) compared to mammography alone (25–
59%), or mammography and ultrasound with or without
clinical examination (49–67%). In considering the use of
MRI, there are no studies which have assessed whether MRI
surveillance reduces the rates of advanced breast cancer
or mortality. Thus, the eﬀectiveness of MRI on improved
survival stems from the assumption that earlier detection
improves survival.
6.2. Ovarian Cancer. To date, no eﬀective screening strategy
has been found for either sporadic or hereditary ovarian
cancer. At this time, the NCCN [52]a n dA C O G[ 54] guide-
lines suggest that for patients with BRCA1 or BRCA2 muta-
tions, pelvic ultrasound and CA125 every 6 months may
be considered for the detection of early ovarian cancer. It
is recommended that screening be initiated at age 35 or 5–10
years prior to the age of the earliest ovarian cancer diagnosis
in an individual’s family.
Studies which have examined ovarian cancer screening
speciﬁcally in BRCA1/2-mutation carriers did not ﬁnd that
pelvic ultrasound and CA125 were eﬀective as a screening
method[63–66].Inaretrospectiveauditof341asymptomat-
ic,high-riskwomenenrolledforovariancancerscreening,31
women underwent explorative surgery because of abnormal
ﬁndings at surveillance. At surgery, 3 cancers were diagnosed
(2 ovarian, 1 endometrial) and 28 women were cancer free,
suggesting that the diagnostic yield in screening women
with a hereditary predisposition is very low [65]. The
largest of the ovarian cancer screening studies for BRCA-
mutation carrier studies included 981 women with BRCA1/2
mutations who underwent screening with annual pelvic
ultrasound and CA125 [63]. The study concluded that there
was no improvement in survival in the cohort of patients
that underwent screening when compared to an unscreened
population.
Importantly, women should be made aware of symp-
tomatology associated with ovarian cancer which should
prompt medical evaluation. Symptoms associated with ovar-
ian cancer include abdominal bloating, urinary urgency
and/or frequency, increased abdominal girth, and early
satiety [67]. Goﬀ et al. attempted to develop a symptom
index for the diagnosis of ovarian cancer by using the symp-
toms previously described with a time frame of symptoms
occurring more than 12 days per month and less than 1
year in duration. The symptom index shows promise for
advanced stage ovarian cancer diagnosis, with a sensitivity
of 79.5% and speciﬁcity nearing 90%. However, for the
detection of early stage disease, the sensitivity value was only
56.7%.
7.SurgicalProphylaxis
Women with a known BRCA1 or BRCA2 mutation should
be oﬀered prophylactic mastectomy and bilateral salpingo-
oophorectomy (BSO) in order to decrease the risk of breast
and ovarian cancer. Bilateral mastectomy decreases breast
cancer risk by 90% [68, 69], and BSO decreases the relative
risk of ovarian and fallopian tube cancer by 80% [70, 71].
However, BSO does not aﬀect the risk of primary peritoneal
cancer [71]. BSO also leads to a reduction of estrogen
stimulation on breast tissue, leading to a 50% relative risk
reduction in the development of breast cancer [71]. The
NCCN recommendation is that mutation carriers are oﬀered
BSO by age 40 or after they have completed childbearing
[52]. Similarly, ESMO recommends prophylactic BSO after
age 35 and when childbearing decisions are complete [56].
Overall, counseling on risk-reducing surgery should take
into account the cumulative risk of developing breast and
ovarian cancer with each decade of life as well as a woman’s
reproductive plans.
To quantify the protective eﬀect of risk-reducing surgery,
Domcheketal.[72]c omplet edalargepr ospecti v e,m ultic en-
ter cohort study which included 2482 women with BRCA1
or BRCA2 mutations ascertained between 1974 and 2008.
There were no breast cancers diagnosed in the 247 women
with prophylactic mastectomy compared with 98 breast
cancers diagnosed in 1372 women who did not undergo a
mastectomy. Compared with women who did not undergo
risk-reducing BSO, undergoing BSO was associated with
lower all-cause mortality (10% versus 3%; HR, 0.40 [95%
CI, 0.26–0.61]). In high risk women who are diagnosed with
breast cancer, a contralateral prophylactic mastectomy in
addition to the therapeutic mastectomy is associated with
a signiﬁcant survival advantage [73]. It has been reported
that only approximately 20–25% of eligible patients choose
to proceed with a prophylactic mastectomy and 50–55%
undergo prophylactic BSO [74, 75]. Predictors of prophy-
lactic surgeries were age below 60 years, personal history of
prior breast cancer and a history of either mastectomy or
BSO [74]. BSO was more common among women younger
than 40 and among parous women [75].
To compare the eﬀectiveness of prophylactic surgery
versus breast screening on the reduction of cancer mortality,
Kurian et al. [76] developed a unique computational model.
Using this model, a 25-year-old BRCA1/2-mutation carrier
was analyzed to compare enrolment in a breast screening
program with annual mammography and MRI from age 25
to69,withprophylacticmastectomyatvariousages+/−BSO
at age 40 or 50. With no intervention, survival probability by
age 70 was estimated at 53% for BRCA1 and 71% for BRCA2
mutation carriers. The most eﬀective single intervention for
BRCA1-mutation carriers was a BSO at age 40, yielding a
15% absolute survival gain. For BRCA2-mutation carriers,
the most eﬀective single intervention was a prophylactic
mastectomy, yielding a 7% survival gain if performed at
age 40. The combination of prophylactic mastectomy and
BSO at the age of 40 improved survival more than any
single intervention, yielding a 24% and 11% survival gain for
BRCA1- and BRCA2-mutation carriers, respectively.
When choosing a surveillance option, patients must be
cautioned that premalignant and malignant changes can
occur in spite of normal radiological investigations. When
prophylactic mastectomy samples were compared between
BRCA1-mutation carriers and healthy controls, there was an
increased incidence of pre-malignant and malignant lesions
detected in BRCA1 prophylactic mastectomy samples (42.3
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of BRCA1 carriers and 2% of BRCA2 carriers who undergo
prophylactic BSO will have occult carcinomas [78]. Hirst
et al. [79] examined the tumours of 45 BRCA-mutation
carriers who underwent a prophylactic BSO and discovered
5occultmalignancies.Recently,insightintothepathogenesis
of hereditary of ovarian cancer has revealed that some
cancers believed to be of primary ovarian origin, in fact,
arise from the fallopian tube [80]. As such, Greene et al.
[81] have suggested that a bilateral salpingectomy with
ovarian retention might serve as a temporary measure while
deﬁnitive risk-reducing surgery is being contemplated in
women who have completed childbearing.
8. Chemoprophylaxis
8.1. Tamoxifen. Tamoxifen is a selective estrogen receptor
modulator that has an inhibitory eﬀect on estrogen receptors
in breast tissue and a proliferative eﬀect in the endometrium.
BRCA-mutation carriers may be oﬀered tamoxifen for
primary prevention of breast cancer [52]. However, since
BRCA1-mutation carriers are more likely to develop ER-
breast tumours, there may be little rationale to support
tamoxifen for the prevention of breast cancer in this
population. The eﬀect of chemoprophylaxis with tamox-
ifen in patients with a hereditary predisposition has been
extrapolated from studies examining the risk of developing
contralateral breast cancer in BRCA1/2-mutation carriers
who were treated with tamoxifen after their primary breast
cancer diagnosis, as well as tamoxifen use in the general
population.
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) initiated the breast cancer prevention trial (P-1)
which enrolled 13,388 high risk patients to determine the
eﬃcacy of tamoxifen in reducing breast cancer risk [82].
This study substantiated that 20mg per day of tamoxifen
for 5 years reduced the risk of primary invasive breast
cancer by 49%. Genomic analysis of BRCA1 and BRCA2
for 288 women who developed breast cancer was completed
after entry into the trial [83]. There were 19 patients with
BRCA1 or BRCA2 mutations. 83% of BRCA1 breast tumours
were ER−, whereas 76% of BRCA2 breast tumours were
ER+. It was concluded that tamoxifen reduced breast cancer
incidence among BRCA2 carriers by 62%, similar to the
reduction of ER+ breast cancer among all women in the
breast cancer prevention trial. In contrast, tamoxifen use
did not reduce breast cancer incidence among women with
inherited BRCA1 mutations. However, the results of the
study were limited by the small number of patients in the
cohort.
Gronwald et al. [84]c o mplet edacasec o ntr olst ud ylook-
ing at BRCA1- and BRCA2-mutation carriers who developed
bilateralbreastcancer(n = 285)versusthosewhohadunilat-
eral breast cancer (n = 781). The multivariate odds ratio for
contralateralbreast cancerassociated with tamoxifen use was
0.50 for carriers of BRCA1 mutations (95% CI, 0.30–0.85)
and 0.42 for carriers of BRCA2 mutations (95% CI, 0.17–
1.02). However, the protective eﬀect of tamoxifen was not
seen among women who had undergone a BSO (OR = 0.83;
95% CI, 0.24–2.89), although there was only a small number
of patients in this subgroup. In contrast, a strong protective
eﬀect of tamoxifen was apparent among women who were
premenopausal or who had undergone natural menopause
(OR = 0.44; 95% CI, 0.27–0.65). This study suggests that
using tamoxifen in BRCA1/2-mutation carriers who have
not undergone a BSO may result in a decreased risk of
breast cancer. It has been estimated that tamoxifen reduces
breastcancerriskinBRCA1-mutationcarriersby13%andin
BRCA2-mutation carriers by 27% [85]. Similar results were
found with respect to the reduction of contralateral breast
cancerriskinpatients witha BRCA1/2mutationtreatedwith
tamoxifen after ﬁrst diagnosis of breast cancer [86, 87].
It has been reported that only 5.5% of women with
a BRCA1 or BRCA2 mutation have used tamoxifen to
reduce their breast cancer risk [88]. Approximately half of
the population at risk relied solely on screening for the
early detection of breast cancer. Patients should be counseled
about the increased risk of endometrial cancer following
tamoxifen treatment (RR = 11.6, P = 0.0004) compared to
BRCA1/2-mutation carriers without a history of tamoxifen
use [89]. Hence, the risks and beneﬁts of prophylactic
hysterectomy should be discussed with those patients. It
has been reported that in BRCA1-associated patients with a
history of breast cancer, subsequent treatment with tamox-
ifen does not increase ovarian cancer risk [90]. Thus, it is
anticipated that primary prophylactic tamoxifen treatment
would not increase ovarian cancer risk.
8.2. Raloxifene. The study of tamoxifen and raloxifene
(STAR) examined the eﬃcacy of tamoxifen and raloxifene to
decrease breast cancer risk [91, 92]. Raloxifene is a selective
estrogen receptor modulator, which is used primarily for
the prevention of osteoporosis. The advantages of raloxifene
a r et h a ti ti sa se ﬀective as tamoxifen in reducing the
risk of invasive breast cancer while having a lower risk
of thromboembolic events and a trend towards a lower
risk of uterine cancer. However, there was a nonstatistically
signiﬁcant higher risk of noninvasive breast cancer observed
with raloxifene. BRCA status was not ascertained in this
study, and, thus, raloxifene eﬃcacy has not speciﬁcally been
evaluated in this patient population.
8.3. Oral Contraceptive Pill (OCP). OCP use has been found
to have diﬀerent eﬀects on the lifetime risk of ovarian and
breast cancer. It has generally been accepted that OCP use
decreases one’s risk of ovarian cancer. However, much debate
has ensued on whether the OCP increases one’s risk of
developing breast cancer. Recently, Iodice et al. [93], have
performed a meta-analysis updated to March 2010 on the
association between OCP use and breast or ovarian cancer in
BRCA1/2-mutation carriers. Based on 18 studies, a total of
2855 breast cancer cases and 1503 ovarian cancer cases were
reviewed. As previously noted, OCP use at any point during
one’s life was associated with a 50% relative risk reduction in
developing ovarian cancer for BRCA1/2-mutation carriers.
Looking speciﬁcally at duration of OCP use, each 10-year
period of OCP use resulted in a 36% relative risk reduction6 International Journal of Spectroscopy
for the development of ovarian cancer. In the meta-analysis,
there was no evidence of a signiﬁcant association between
OCPuseandbreastcancerrisk(summaryrelativerisk(SRR):
1.13; 95% CI, 0.88–1.45). Speciﬁcally, OCP formulations
used before 1975 correlated with an increased risk of breast
cancer (SRR: 1.47; 95% CI: 1.06, 2.04), but there was no
correlation with the use of more recent formulations (SRR:
1.17; 95% 0.74,1.86). There are studies which have correlated
past users of the OCP to an increased risk of breast cancer
[26, 94].
Figueiredo et al. [95] examined the eﬀect of oral
contraceptives and hormone replacement therapy (HRT) on
the development of contralateral breast cancer in BRCA1/2-
mutation carriers with a history of breast cancer. OCP use
was not associated with increased contralateral breast cancer
risk in BRCA2-mutation carriers (RR = 0.82; 95% CI =
0.21–3.13), and BRCA1-mutaion carriers who used the OCP
trended towards a greater risk of contralateral breast cancer
compared to nonusers, but this risk was not signiﬁcant
(RR = 2.38; 95% CI = 0.72–7.83). Few women had ever
used HRT and there were no signiﬁcant associations found
between lifetime use and contralateral breast cancer risk
among BRCA1/2-mutation carriers and noncarriers.
9.HereditaryBreastandOvarian
Cancer andHRT
Known BRCA1/2 carriers often choose to undergo a risk-
reducing BSO, thereby, entering a surgical menopause at
an earlier age. As such, many would beneﬁt from HRT to
help alleviate menopausal symptoms. Rebbeck et al. [96]
completed a prospective cohort study looking at 462 women
with BRCA1/2 mutations to evaluate breast cancer risk after
BSO with and without HRT use. They found that BSO
was signiﬁcantly associated with breast cancer risk reduction
overall(hazardratio[HR]=0.40;95%CI,0.18to0.92).HRT
of any type after BSO did not signiﬁcantly alter the reduction
in breast cancer risk (HR = 0.37; 95% CI, 0.14 to 0.96) when
compared to women who have not had a BSO or used HRT.
In a matched case-control study of 472 postmenopausal
women with a BRCA1 mutation, the adjusted odds ratio for
breastcancerinHRTusersversusnonuserswas0.58(95%CI
= 0.35 to 0.96; P = 0.03) [97]. Overall, it appears that short-
termHRTusedoesnotnegatetheprotectiveeﬀectofBSOon
subsequent breast cancer risk in BRCA1/2-mutation carriers.
Recently, the MARIE-GENICA Consortium on Genetic
Susceptibility for Menopausal Hormone Therapy Related
Breast Cancer Risk [98] has investigated HRT use and
breast cancer risk in 3,149 postmenopausal breast cancer
patients and 5,489 controls from the two German case-
control studies. The study was initiated to determine the
modiﬁcation of breast cancer risk associated with hormone
usebyasubsetofgenesinvolvedinhormonemetabolismand
cell cycle regulation, of which BRCA1 is included. A minor
allele of BRCA1, which carries an amino acid substitution
duetoasinglenucleotidepolymorphism, wasfoundtoaﬀect
the interaction with both RAD51 as well as the androgen
receptor [98]. Preliminary evidence trended towards an
increased risk in postmenopausal breast cancer in BRCA1
minorallelecarriersonestrogenhormonetherapycompared
to those with the major BRCA1 allele genotype.
10.BRCAness and SporadicCancer
The concept of “BRCAness” has evolved to reﬂect the traits
that some sporadic cancers share with BRCA1/2-mutation
carriers [99]. The inactivation of BRCA1 is a relatively fre-
quent event in sporadic ovarian cancer and has been shown
to occur through a number of epigenetic mechanisms such
as promoter hypermethylation and loss of heterozygosity
[100]. Decreased BRCA1 expression has been found in
approximately 30–40% of sporadic breast cancers [101]a n d
15–80% of ovarian cancers [102]. BRCA1 has recently been
evaluated as a tumour biomarker in a number of malig-
nancies including ovarian [103, 104], breast [105, 106]a n d
nonsmall cell lung cancer [107].
Emerging evidence suggests that tumours may be char-
acterized by a relative level of BRCA1 deﬁciency at both
the mRNA and protein level, resulting in BRCA1 having a
potentially broader clinical relevance as a prognostic and
predictive marker for patients with sporadic disease. A study
in sporadic breast cancer by Margeli’s group [108]f o u n d
that patients with lower BRCA1 mRNA expression who
were treated with neoadjuvant chemotherapy (ﬂuorouracil,
epirubicin, and cyclophosphamide) had a lower relapse rate
and longer survival when compared to patients with higher
BRCA1 expression. An analysis of 70 tumours from patients
with sporadic ovarian cancer for BRCA1 mRNA expression
correlated low BRCA1 mRNA expression with improved
survivalfollowingplatinum-basedchemotherapy[109].This
ﬁnding was supported by our group which associated low
BRCA1 mRNA expression with improved overall survival in
51 patients with sporadic ovarian cancer [104]. Thrall et al.
[103] examined BRCA1 protein expression in 230 sporadic
ovarian cancers and demonstrated that compared to high
BRCA1 expression, low BRCA1 expression was predictive
of longer overall survival (aHR = 0.51 (95% CI 0.32–0.83).
Recently, our group has showed that in optimally debulked
advanced ovarian cancer patients treated with platinum-
based chemotherapy, low BRCA1 protein expression was sig-
niﬁcantly associated with a better progression-free survival
(PFS) (median PFS was 24.7 and 16.6 months in patients
with low and high BRCA1, resp.; HR = 0.56) [110]. Such
ﬁndings extend the clinical importance of BRCA in women
with breast and ovarian cancer patients, and further study is
needed to explore BRCA as a predictive marker to targeted
therapies.
11. Targeted Therapies for
BRCA-Deﬁcient Tumours
WhileDNAdefectsareoftenastepintheprocessoftumouri-
genesis, once a cell becomes cancerous, such defects may
be exploitable to enhance susceptibility to chemotherapeutic
agents. It is well accepted that BRCA1 deﬁciency leads to the
dysregulationofDNArepairpathways,whichinturnrendersInternational Journal of Spectroscopy 7
tumour cells more vulnerable to DNA damaging agents
such as platinum-based chemotherapy. Poly (ADP-ribose)
polymeraseinhibitors(PARPi)areanoveltherapeuticoption
for the treatment of ovarian and breast cancers which
preferentially target BRCA1-defective cells and spare those
with normal function [111]. The PARP family of enzymes
servesavitalroleintherepairofsingle-strandedDNAbreaks
(SSBs). Normally, unrepaired SSBs lead to double-strand
breaks (DSBs), which are subsequently repaired in cells with
normal BRCA function. However, in cells where BRCA is
nonfunctioning or deﬁcient, DSB are left unrepaired, leading
to genomic instability and cell death [111]. The use of the
PARP1 and PARP2 inhibitor, olaparib, has been studied in a
phase I clinical trial for the treatment of advanced breast and
ovarian cancer patients with BRCA1/2 germline mutation
as well as in a phase II trial in advanced breast cancer
patientswithBRCA1/2mutations,withbothstudiesshowing
promising results [112, 113]. A number of clinical trials are
currently ongoing with the use of various PARP inhibitors,
bothassingleagentsandincombinationwithchemotherapy,
for both hereditary and sporadic breast and ovarian cancer.
12. Conclusion
Hereditary breast and ovarian cancer patients are unique in
terms of age of diagnosis, pathological features, and prog-
nosis. Clinicians working in the area of surgical oncology
should be familiar with the criteria for referral of high-risk
individuals for genetic testing. BRCA1/2- mutation carriers
should be oﬀered risk reduction strategies, in the form of
prophylactic bilateral mastectomy and/or bilateral salpingo-
oophorectomy at an early age. If a patient declines surgery,
appropriate screening should ensue with an understanding
of the limitations that exist. Chemoprevention with tamox-
ifen or raloxifene is used to decrease ones risk of breast
cancer, and OCPs may be used eﬀectively to reduce the
risk of ovarian cancer. New evidence suggests that BRCA
has a broader role as a potential biomarker in sporadic
breast/ovarian cancer for the management of this patient
population. Targeted therapy with PARPi is an exciting novel
treatment option being tested in clinical trials, particularly
for ovarian cancer patients where chemotherapy is limited.
Conﬂict of Interests
The authors have declared that there are no conﬂicts of inter-
ests.
Abbreviations
BRCA1: Breast cancer protein 1
ER: Estrogen receptor
BSO: Bilateral salpingo-oopherectomy
OCP: Oral contraceptive pill
HRT: Hormone replacement therapy
PARPi: Poly(ADP-ribose) polymerase inhibitors
RR: Relative risk.
Acknowledgments
This work was supported by the Ottawa Regional Cancer
Foundation (J.I.W.), the Department of Obstetrics and
Gynecology, (J.I.W.) and the Division of Gynecologic Oncol-
ogy, Ottawa.
References
[ 1 ] E .v a nR i e l ,C .C .W´ arl´ a m - R o d e n h u i s ,S .V e r h o e f ,E .R u t g e r s ,
and M. Ausems, “BRCA testing of breast cancer patients:
medicalspecialists’referralpatterns,knowledgeandattitudes
to genetic testing,” European Journal of Cancer Care, vol. 19,
no. 3, pp. 369–376, 2010.
[2] American Cancer Society, “Breast cancer facts and ﬁgures
2009-2010,” 2009.
[3] American Cancer Society, “Cancer facts and ﬁgures,” 2010.
[4] M. R. McClain, G. E. Palomaki, K. L. Nathanson, and J. E.
Haddow, “Adjusting the estimated proportion of breast can-
cer cases associated with BRCA1 and BRCA2 mutations:
public health implications,” Genetics in Medicine, vol. 7, no.
1, pp. 28–33, 2005.
[5] E. M. John, A. Miron, G. Gong et al., “Prevalence of patho-
genicBRCA1mutationcarriersin5USracial/ethnicgroups,”
Journal of the American Medical Association, vol. 298, no. 24,
pp. 2869–2876, 2007.
[6] K.E.M alone,J .R.Daling,D .R.Doodyetal.,“P revalenceand
predictors of BRCA1 and BRCA2 mutations in a population-
based study of breast cancer in White and Black American
women ages 35 to 64 years,” Cancer Research, vol. 66, no. 16,
pp. 8297–8308, 2006.
[7] T. Pal, J. Permuth-Wey, J. A. Betts et al., “BRCA1 and BRCA2
mutations account for a large proportion of ovarian carcino-
ma cases,” Cancer, vol. 104, no. 12, pp. 2807–2816, 2005.
[ 8 ]S .Z h a n g ,R .R o y e r ,S .L ie ta l . ,“ F r e q u e n c i e so fB R C A 1a n d
BRCA2 mutations among 1,342 unselected patients with in-
vasive ovarian cancer,” Gynecologic Oncology, vol. 121, no. 2,
pp. 353–357, 2011.
[9] H.A.Risch,J.R.McLaughlin,D.E.C.Coleetal.,“Population
BRCA1 and BRCA2 mutation frequencies and cancer pene-
trances: a kin-cohort study in Ontario, Canada,” Journal of
the National Cancer Institute, vol. 98, no. 23, pp. 1694–1706,
2006.
[10] “Prevalence and penetrance of BRCA1 and BRCA2 muta-
tions in a population-based series of breast cancer cases.
Anglian Breast Cancer Study Group,” British Journal of
Cancer, vol. 83, pp. 1301–1308, 2000.
[11] K. E. Malone, J. R. Daling, C. Neal et al., “Frequency of
BRCA1/BRCA2 mutations in a population-based sample of
young breast carcinoma cases,” Cancer,v o l .8 8 ,n o .6 ,p p .
1393–1402, 2000.
[ 1 2 ]M .C .K i n g ,J .H .M a r k s ,J .B .M a n d e l l ,a n dN e wY o r kB r e a s t
Cancer Study Group, “Breast and Ovarian Cancer Risks Due
to Inherited Mutations in BRCA1 and BRCA2,” Science, vol.
302, no. 5645, pp. 643–646, 2003.
[13] A. Antoniou, P. D. P. Pharoah, S. Narod et al., “Average risks
of breast and ovarian cancer associated with BRCA1 or
BRCA2 mutations detected in case series unselected for
family history: a combined analysis of 22 studies,” American
Journal of Human Genetics, vol. 72, no. 5, pp. 1117–1130,
2003.8 International Journal of Spectroscopy
[14] D. M. van der Kolk, G. H. de Bock, B. K. Leegte et al.,
“Penetrance of breast cancer, ovarian cancer and contralat-
eral breast cancer in BRCA1 and BRCA2 families: high
cancer incidence at older age,” Breast Cancer Research and
Treatment, vol. 124, no. 3, pp. 643–651, 2010.
[15] E. Warner, W. Foulkes, P. Goodwin et al., “Prevalence
and penetrance of BRCA1 and BRCA2 gene mutations in
unselected Ashkenazi Jewish women with breast cancer,”
Journal of the National Cancer Institute, vol. 91, no. 14, pp.
1241–1247, 1999.
[16] B. B. Roa, A. A. Boyd, K. Volcik, and C. S. Richards, “Ashke-
nazi jewish population frequencies for common mutations
in BRCA1 and BRCA2,” Nature Genetics, vol. 14, no. 2, pp.
185–187, 1996.
[17] B. Modan, P. Hartge, G. Hirsh-Yechezkel et al., “Parity, oral
contraceptives, and the risk of ovarian cancer among carriers
a n dn o n c a r r i e r so faB R C A 1o rB R C A 2m u t a t i o n , ”New
England Journal of Medicine, vol. 345, no. 4, pp. 235–240,
2001.
[18] A. Veronesi, C. de Giacomi, M. D. Magri et al., “Familial
breast cancer: characteristics and outcome of BRCA 1-2
positive and negative cases,” BMC Cancer, vol. 5, article 70,
2005.
[19] L. Kadouri, A. Hubert, Y. Rotenberg et al., “Cancer risks
in carriers of the BRCA1/2 Ashkenazi founder mutations,”
Journal of Medical Genetics, vol. 44, no. 7, pp. 467–471, 2007.
[20] D. Thompson and D. F. Easton, “Cancer incidence in BRCA1
mutation carriers,” Journal of the National Cancer Institute,
vol. 94, no. 18, pp. 1358–1365, 2002.
[21] C. Cybulski, B. G´ orski, J. Gronwald et al., “BRCA1 mutations
and prostate cancer in Poland,” European Journal of Cancer
Prevention, vol. 17, no. 1, pp. 62–66, 2008.
[22] J. Suchy, C. Cybulski, B. G´ orski et al., “BRCA1 mutations and
colorectalcancerinPoland,”FamilialCancer,v ol.9,no .4,pp .
541–544, 2010.
[23] D. Easton, “Cancer risks in BRCA2 mutation carriers: the
breast cancer linkage consortium,” Journal of the National
Cancer Institute, vol. 91, no. 15, pp. 1310–1316, 1999.
[24] T. Kirchhoﬀ,N .D .K a u ﬀ, N. Mitra et al., “BRCA mutations
and risk of prostate cancer in ashkenazi jews,” Clinical Cancer
Research, vol. 10, no. 9, pp. 2918–2921, 2004.
[ 2 5 ]K .M .M u r p h y ,K .A .B r u n e ,C .G r i ﬃn et al., “Evaluation of
candidategenesMAP2K4,MADH4,ACVR1B,andBRCA2in
familial pancreatic cancer: deleterious BRCA2 mutations in
17%,” Cancer Research, vol. 62, no. 13, pp. 3789–3793, 2002.
[26] R. M. Brohet, D. E. Goldgar, D. F. Easton et al., “Oral
contraceptives and breast cancer risk in the international
BRCA1/2 carrier cohort study: a report from EMBRACE,
GENEPSO, GEO-HEBON, and the IBCCS collaborating
group,”JournalofClinicalOncology,vol.25,no.25,pp.3831–
3836, 2007.
[27] T. Debniak, R. J. Scott, B. G´ orski et al., “Common variants
of DNA repair genes and malignant melanoma,” European
Journal of Cancer, vol. 44, no. 1, pp. 110–114, 2008.
[28] D. P. Atchley, C. T. Albarracin, A. Lopez et al., “Clinical and
pathologic characteristics of patients with BRCA-positive
and BRCA-negative breast cancer,” Journal of Clinical Oncol-
ogy, vol. 26, no. 26, pp. 4282–4288, 2008.
[29] N. Tung, Y. Wang, L. C. Collins et al., “Estrogen receptor
positive breast cancers in BRCA1 mutation carriers: clinical
risk factors and pathologic features,” Breast Cancer Research,
vol. 12, no. 1, article R12, 2010.
[30] N. Loman, O. Johannsson, P. O. Bendahl, Borg, M. Fern¨ o,
and H. Olsson, “Steroid receptors in hereditary breast car-
cinomas associated with BRCA1 or BRCA2 mutations or
unknown susceptibility genes,” Cancer, vol. 83, no. 2, pp.
310–319, 1998.
[31] O. T. Johannsson, I. Idvall, C. Anderson et al., “Tumour bio-
logical features of BRCA1-induced breast and ovarian can-
cer,”EuropeanJournalofCancerA,vol.33,no.3,pp.362–371,
1997.
[ 3 2 ] A .M u s o l i n o ,M .A .B e l l a ,B .B o r t e s ie ta l . ,“ B R C Am u t a t i o n s ,
molecular markers, and clinical variables in early-onset
breast cancer: a population-based study,” Breast, vol. 16, no.
3, pp. 280–292, 2007.
[33] E. H. Lee, S. K. Park, B. Park et al., “Eﬀect of BRCA1/2 muta-
tion on short-term and long-term breast cancer survival: a
systematic review and meta-analysis,” Breast Cancer Research
and Treatment, vol. 122, no. 1, pp. 11–25, 2010.
[34] T. Byrski, J. Gronwald, T. Huzarski et al., “Pathologic com-
plete response rates in young women with BRCA1-positive
breast cancers after neoadjuvant chemotherapy,” Journal of
Clinical Oncology, vol. 28, no. 3, pp. 375–379, 2010.
[35] J. Boyd, Y. Sonoda, M. G. Federici et al., “Clinicopatholic
features of BRCA-linked and sporadic ovarian cancer,”
Journal of the American Medical Association, vol. 283, no. 17,
pp. 2260–2265, 2000.
[36] J. M. J. Piek, B. Torrenga, B. Hermsen et al., “Histopatho-
logical characteristics of BRCA1- and BRCA2-associated
intraperitoneal cancer: a clinic-based study,” Familial Cancer,
vol. 2, no. 2, pp. 73–78, 2003.
[37] R. A. Lacour, S. N. Westin, L. A. Meyer et al., “Improved
survival in non-Ashkenazi Jewish ovarian cancer patients
with BRCA1 and BRCA2 gene mutations,” Gynecologic
Oncology, vol. 121, no. 2, pp. 358–363, 2011.
[38] A. Chetrit, G. Hirsh-Yechezkel, Y. Ben-David, F. Lubin, E.
Friedman, and S. Sadetzki, “Eﬀect of BRCA1/2 mutations on
long-term survival of patients with invasive ovarian cancer:
the National Israeli Study of Ovarian Cancer,” Journal of
Clinical Oncology, vol. 26, no. 1, pp. 20–25, 2008.
[39] J. M. Hall, M. K. Lee, B. Newman et al., “Linkage of early-
onset familial breast cancer to chromosome 17q21,” Science,
vol. 250, no. 4988, pp. 1684–1689, 1990.
[40] R. Wooster, S. L. Neuhausen, J. Mangion et al., “Localization
of a breast cancer susceptibility gene, BRCA2, to chromo-
some 13q12-13,” Science, vol. 265, no. 5181, pp. 2088–2090,
1994.
[41] A. Meindl, “Comprehensive analysis of 989 patients with
breast or ovarian cancer provides BRCA1 and BRCA2 muta-
tion proﬁles and frequencies for the German population,”
International Journal of Cancer, vol. 97, no. 4, pp. 472–480,
2002.
[42] J. P. Struewing, P. Hartge, S. Wacholder et al., “The risk
of cancer associated with speciﬁc mutations of BRCA1 and
BRCA2 among Ashkenazi Jews,” New England Journal of
Medicine, vol. 336, no. 20, pp. 1401–1408, 1997.
[43] K. J. Patel, V. P. C. C. Yu, H. Lee et al., “Involvement of Brca2
in DNA repair,” Molecular Cell, vol. 1, no. 3, pp. 347–357,
1998.
[44] M. E. Moynahan, J. W. Chiu, B. H. Koller, and M. Jasint,
“Brca1 controls homology-directed DNA repair,” Molecular
Cell, vol. 4, no. 4, pp. 511–518, 1999.
[45] M. E. Moynahan, A. J. Pierce, and M. Jasin, “BRCA2
is required for homology-directed repair of chromosomal
breaks,” Molecular Cell, vol. 7, no. 2, pp. 263–272, 2001.International Journal of Spectroscopy 9
[46] R. Scully, J. Chen, A. Plug et al., “Association of BRCA1 with
Rad51 in mitotic and meiotic cells,” Cell,v o l .8 8 ,n o .2 ,p p .
265–275, 1997.
[47] S. K. Sharan, M. Morimatsu, U. Albrecht et al., “Embryonic
lethalityandradiationhypersensitivitymediatedbyRad51in
mice lacking Brca2,” Nature, vol. 386, no. 6627, pp. 804–810,
1997.
[48] F. Xia, D. G. Taghian, J. S. DeFrank et al., “Deﬁciency of
human BRCA2 leads to impaired homologous recombina-
tion but maintains normal nonhomologous end joining,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 98, no. 15, pp. 8644–8649, 2001.
[49] J. L. Berliner and A. M. Fay, “Risk assessment and genetic
counseling for hereditary breast and ovarian cancer: recom-
mendations of the National Society of Genetic Counselors,”
Journal of Genetic Counseling, vol. 16, no. 3, pp. 241–260,
2007.
[50] D. G. R. Evans, F. Lalloo, A. Cramer et al., “Addition of
pathology and biomarker information signiﬁcantly improves
the performance of the Manchester scoring system for
BRCA1 and BRCA2 testing,” Journal of Medical Genetics, vol.
46, no. 12, pp. 811–817, 2009.
[51] J. E. Stopfer, “Genetic counseling and clinical cancer genetics
services,” Seminars in Surgical Oncology,v o l .1 8 ,n o .4 ,p p .
347–357, 2000.
[52] M. B. Daly, J. E. Axilbund, S. Buys et al., “Genetic/familial
high-risk assessment: breast and ovarian—clinical practice
guidelines in oncologyTM,” Journal of the National Compre-
hensive Cancer Network, vol. 8, no. 5, pp. 562–594, 2010.
[53] U.S. Preventive Services Task Force, “Genetic risk assessment
and BRCA mutation testing for breast and ovarian cancer
susceptibility: recommendation statement,” Annals of Inter-
nal Medicine, vol. 143, pp. 355–361, 2005.
[54] American Congress of Obstetricians and Gynecologists Bul-
letins, “Hereditary breast and ovarian cancer syndrome,”
Gynecologic Oncology, vol. 113, pp. 6–11, 2009.
[55] National Institute for Health and Clinical Excellence, “Famil-
ial breast cancer: the classiﬁcation and care of women at risk
of familial breast cancer in primary, secondary and tertiary
care,” 2006.
[56] J. Balma˜ n a ,O .D ´ ıez, and M. Castiglione, “BRCA in breast
cancer: ESMO clinical recommendations,” Annals of Oncol-
ogy, vol. 20, supplement 4, pp. 19–20, 2009.
[57] M. L. Holland, A. Huston, and K. Noyes, “Cost-eﬀectiveness
of testing for breast cancer susceptibility genes,” Value in
Health, vol. 12, no. 2, pp. 207–216, 2009.
[ 5 8 ]W .A .B e r g ,J .D .B l u m e ,J .B .C o r m a c ke ta l . ,“ C o m b i n e d
screening with ultrasound and mammography vs mammog-
raphy alone in women at elevated risk of breast cancer,”
Journal of the American Medical Association, vol. 299, no. 18,
pp. 2151–2163, 2008.
[59] A. I. Hagen, K. A. Kvistad, L. Maehle et al., “Sensitivity of
MRIversusconventionalscreeninginthediagnosisofBRCA-
associated breast cancer in a national prospective series,”
Breast, vol. 16, no. 4, pp. 367–374, 2007.
[60] A. J. Rijnsburger, I.-M. Obdeijn, R. Kaas et al., “BRCA1-
associated breast cancers present diﬀerently from BRCA2-
associated and familial cases: long-term follow-up of the
Dutch MRISC screening study,” Journal of Clinical Oncology,
vol. 28, no. 36, pp. 5265–5273, 2010.
[61] G. Trecate, D. Vergnaghi, S. Manoukian et al., “MRI in the
early detection of breast cancer in women with high genetic
risk,” Tumori, vol. 92, no. 6, pp. 517–523, 2006.
[62] S. J. Lord, W. Lei, P. Craft et al., “A systematic review of
the eﬀectiveness of magnetic resonance imaging (MRI) as
an addition to mammography and ultrasound in screening
youngwomen at highriskofbreastcancer,” EuropeanJournal
of Cancer, vol. 43, no. 13, pp. 1905–1917, 2007.
[63] D.G.Evans,K.N.Gaarenstroom,D.Stirlingetal.,“Screening
for familial ovarian cancer: poor survival of BRCA1/2 related
cancers,” Journal of Medical Genetics, vol. 46, no. 9, pp. 593–
597, 2009.
[64] H. F. A. Vasen, E. Tesfay, H. Boonstra et al., “Early detection
of breast and ovarian cancer in families with BRCA muta-
tions,”EuropeanJournalofCancer,vol.41,no.4,pp.549–554,
2005.
[65] E. R. Woodward, H. V. Sleightholme, A. M. Considine,
S. Williamson, J. M. McHugo, and D. G. Cruger, “Annual
surveillance by CA125 and transvaginal ultrasound for
ovarian cancer in both high-risk and population risk women
is ineﬀective,” International Journal of Obstetrics and Gynae-
cology, vol. 114, no. 12, pp. 1500–1509, 2007.
[66] N. M. van der Velde, M. J. E. Mourits, H. J. G. Arts et al.,
“Time to stop ovarian cancer screening in BRCA1/2 muta-
tion carriers?” International Journal of Cancer, vol. 124, pp.
919–923, 2009.
[67] B. A. Goﬀ, L. S. Mandel, C. W. Drescher et al., “Development
of an ovarian cancer symptom index: possibilities for earlier
detection,” Cancer, vol. 109, no. 2, pp. 221–227, 2007.
[68] L. C. Hartmann, T. A. Sellers, D. J. Schaid et al., “Eﬃcacy
of bilateral prophylactic mastectomy in BRCA1 and BRCA2
gene mutation carriers,” Journal of the National Cancer
Institute, vol. 93, no. 21, pp. 1633–1637, 2001.
[69] T.R.Rebbeck,T.Friebel,H.T.Lynchetal.,“Bilateralprophy-
lactic mastectomy reduces breast cancer risk in BRCA1 and
BRCA2 mutation carriers: the PROSE study group,” Journal
of Clinical Oncology, vol. 22, no. 6, pp. 1055–1062, 2004.
[70] A. Finch, M. Beiner, J. Lubinski et al., “Salpingo-oophorec-
tomy and the risk of ovarian, fallopian tube, and peritoneal
cancers in women with a BRCA1 or BRCA2 mutation,”
Journal of the American Medical Association, vol. 296, no. 2,
pp. 185–192, 2006.
[71] T. R. Rebbeck, N. D. Kauﬀ, and S. M. Domchek, “Meta-
analysis of risk reduction estimates associated with risk-
reducing salpingo-oophorectomy in BRCA1 or BRCA2
mutation carriers,” Journal of the National Cancer Institute,
vol. 101, no. 2, pp. 80–87, 2009.
[72] S. M. Domchek, T. M. Friebel, C. F. Singer et al., “Association
of risk-reducing surgery in BRCA1 or BRCA2 mutation
carriers with cancer risk and mortality,” Journal of the
American Medical Association, vol. 304, no. 9, pp. 967–975,
2010.
[73] J. C. Boughey, T. L. Hoskin, A. C. Degnim et al., “Contralat-
eral prophylactic mastectomy is associated with a survival
advantage in high-risk women with a personal history of
breast cancer,” Annals of Surgical Oncology, vol. 17, no. 10,
pp. 2702–2709, 2010.
[74] M. S. Beattie, B. Crawford, F. Lin, E. Vittinghoﬀ,a n dJ .
Ziegler,“Uptake,timecourse,andpredictorsofrisk-reducing
surgeries in BRCA carriers,” Genetic Testing and Molecular
Biomarkers, vol. 13, no. 1, pp. 51–56, 2009.
[75] T. M. Friebel, S. M. Domchek, S. L. Neuhausen et al., “Bilat-
eral prophylactic oophorectomy and bilateral prophylactic
mastectomyinaprospectivecohortofunaﬀectedBRCA1and
BRCA2 mutation carriers,” Clinical Breast Cancer, vol. 7, no.
11, pp. 875–882, 2007.10 International Journal of Spectroscopy
[76] A. W. Kurian, B. M. Sigal, and S. K. Plevritis, “Survival analy-
sis of cancer risk reduction strategies for BRCA1/2 mutation
carriers,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 222–
231, 2010.
[77] R. Kroiss, V. Winkler, K. Kalteis et al., “Prevalence of pre-
malignantandmalignantlesionsinprophylacticmastectomy
specimens of BRCA1 mutation carriers: comparison with
a control group,” Journal of Cancer Research and Clinical
Oncology, vol. 134, no. 10, pp. 1113–1121, 2008.
[78] A. Finch, P. Shaw, B. Rosen, J. Murphy, S. A. Narod, and
T.J.Colgan,“Clinicalandpathologicﬁndingsofprophylactic
salpingo-oophorectomies in 159 BRCA1 and BRCA2 carri-
ers,” Gynecologic Oncology, vol. 100, no. 1, pp. 58–64, 2006.
[79] J. E. Hirst, G. B. Gard, K. Mcillroy, D. Nevell, and M. Field,
“High rates of occult fallopian tube cancer diagnosed at
prophylactic bilateral salpingo-oophorectomy,” International
Journal of Gynecological Cancer, vol. 19, no. 5, pp. 826–829,
2009.
[80] S. Salvador, B. Gilks, M. K¨ o b e l ,D .H u n t s m a n ,B .R o s e n ,a n d
D. Miller, “The fallopian tube: primary site of most pelvic
high-grade serous carcinomas,” International Journal of Gy-
necological Cancer, vol. 19, no. 1, pp. 58–64, 2009.
[81] M. H. Greene, P. L. Mai, and P. E. Schwartz, “Does bilateral
salpingectomy with ovarian retention warrant consideration
as a temporary bridge to risk-reducing bilateral oophorec-
tomy in BRCA1/2 mutation carriers?” American Journal of
Obstetrics and Gynecology, vol. 204, no. 1, pp. 19.e1–19.e6,
2011.
[82] B.Fisher,J.P.Costantino,D.L.Wickerhametal.,“Tamoxifen
for prevention of breast cancer: report of the National
Surgical Adjuvant Breast and Bowel Project P-1 study,”
Journal of the National Cancer Institute, vol. 90, no. 18, pp.
1371–1388, 1998.
[83] M. C. King, S. Wieand, K. Hale et al., “Tamoxifen and breast
cancer incidence among women with inherited mutations in
brca1 and brca2 national surgical adjuvant breast and bowel
project (nsabp-p1) breast cancer prevention trial,” Journal of
the American Medical Association, vol. 286, no. 18, pp. 2251–
2256, 2001.
[84] J. Gronwald, N. Tung, W. D. Foulkes et al., “Tamoxifen and
contralateral breast cancer in BRCA1 and BRCA2 carriers: an
update,” International Journal of Cancer, vol. 118, no. 9, pp.
2281–2284, 2006.
[85] S. W. Duﬀy and R. M. Nixon, “Estimates of the likely pro-
phylacticeﬀectoftamoxifeninwomenwithhighriskBRCA1
and BRCA2 mutations,” British Journal of Cancer, vol. 86, no.
2, pp. 218–221, 2002.
[86] K. Metcalfe, H. T. Lynch, P. Ghadirian et al., “Contralateral
breast cancer in BRCA1 and BRCA2 mutation carriers,”
Journal of Clinical Oncology, vol. 22, no. 12, pp. 2328–2335,
2004.
[87] S. A. Narod, J. S. Brunet, P. Ghadirian et al., “Tamoxifen
and risk of contralateral breast cancer in BRCA1 and BRCA2
mutation carriers: a case-control study. Hereditary Breast
CancerClinicalStudyGroup,”TheLancet,vol.356,pp.1876–
1881, 2000.
[88] K. A. Metcalfe, D. Birenbaum-Carmeli, J. Lubinski et al.,
“International variation in rates of uptake of preventive
options in BRCA1 and BRCA2 mutation carriers,” Interna-
tional Journal of Cancer, vol. 122, no. 9, pp. 2017–2022, 2008.
[89] M. E. Beiner, A. Finch, B. Rosen et al., “The risk of endome-
trial cancer in women with BRCA1 and BRCA2 mutations. A
prospective study,” Gynecologic Oncology, vol. 104, no. 1, pp.
7–10, 2007.
[90] D. Vicus, B. Rosen, J. Lubinski et al., “Tamoxifen and the risk
of ovarian cancer in BRCA1 mutation carriers,” Gynecologic
Oncology, vol. 115, no. 1, pp. 135–137, 2009.
[91] V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Eﬀects
of tamoxifen vs raloxifene on the risk of developing invasive
breast cancer and other disease outcomes: the NSABP Study
of Tamoxifen and Raloxifene (STAR) P-2 trial,” Journal of
the American Medical Association, vol. 295, no. 23, pp. 2727–
2741, 2006.
[92] V. G. Vogel, J. P. Costantino, D. L. Wickerham et al., “Erra-
tum: eﬀects of tamoxifen vs raloxifene on the risk of devel-
oping invasive breast cancer and other disease outcomes: the
NSABPStudyofTamoxifenandRaloxifene(STAR)P-2trial,”
Journal of the American Medical Association, vol. 298, no. 9, p.
973, 2007.
[93] S. Iodice, M. Barile, N. Rotmensz et al., “Oral contraceptive
use and breast or ovarian cancer risk in BRCA1/2 carriers: a
meta-analysis,” European Journal of Cancer, vol. 46, no. 12,
pp. 2275–2284, 2010.
[94] S. A. Narod, M. P. Dub´ e, J. Klijn et al., “Oral contraceptives
and the risk of breast cancer in BRCA1 and BRCA2 mutation
carriers,” Journal of the National Cancer Institute, vol. 94, no.
23, pp. 1773–1779, 2002.
[95] J. C. Figueiredo, R. W. Haile, L. Bernstein et al., “Oral con-
traceptives and postmenopausal hormones and risk of con-
tralateral breast cancer among BRCA1 and BRCA2 mutation
carriers and noncarriers: the WECARE Study,” Breast Cancer
Research and Treatment, vol. 120, no. 1, pp. 175–183, 2010.
[96] T. R. Rebbeck, T. Friebel, T. Wagner et al., “Eﬀect of short-
term hormone replacement therapy on breast cancer risk
reduction after bilateral prophylactic oophorectomy in
BRCA1 and BRCA2 mutation carriers: the PROSE Study
Group,” Journal of Clinical Oncology, vol. 23, no. 31, pp.
7804–7810, 2005.
[97] A. Eisen, J. Lubinski, J. Gronwald et al., “Hormone therapy
and the risk of breast cancer in BRCA1 mutation carriers,”
Journal of the National Cancer Institute, vol. 100, no. 19, pp.
1361–1367, 2008.
[98] S. Abbas, L. Beckmann, J. Changclaude et al., “Polymor-
phisms in the BRCA1 and ABCB1 genes modulate men-
opausal hormone therapy associated breast cancer risk in
postmenopausal women,” Breast Cancer Research and Treat-
ment, vol. 120, no. 3, pp. 727–736, 2010.
[99] N. Turner, A. Tutt, and A. Ashworth, “Hallmarks of
‘BRCAness’ in sporadic cancers,” Nature Reviews Cancer, vol.
4, no. 10, pp. 814–819, 2004.
[100] C. Bozzetti, B. Bortesi, and C. Merisio, “Loss of heterozy-
gosity (LOH) in ovarian cancer,” International Journal of
Gynecology and Obstetrics, vol. 85, no. 3, pp. 294–295, 2004.
[101] V. Birgisdottir, O. A. Stefansson, S. K. Bodvarsdottir, H.
Hilmarsdottir, J. G. Jonasson, and J. E. Eyfjord, “Epigenetic
silencing and deletion of the BRCA1 gene in sporadic breast
cancer,” Breast Cancer Research, vol. 8, no. 4, article R38,
2006.
[102] J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden,
“Sporadic epithelial ovarian cancer: clinical relevance of
brca1 inhibition in the DNA damage and repair pathway,”
Journal of Clinical Oncology, vol. 26, no. 19, pp. 3259–3267,
2008.
[103] M. Thrall, H. H. Gallion, R. Kryscio, M. Kapali, D. K. Arm-
strong, and J. A. Deloia, “BRCA1 expression in a large seriesInternational Journal of Spectroscopy 11
of sporadic ovarian carcinomas: a Gynecologic Oncology
Group study,” International Journal of Gynecological Cancer,
vol. 16, no. 1, pp. 166–171, 2006.
[104] J. Weberpals, K. Garbuio, A. O’Brien et al., “The DNA
repair proteins BRCA1 and ERCC1 as predictive markers in
sporadic ovarian cancer,” InternationalJournalofCancer, vol.
124, pp. 806–815, 2009.
[105] H. Lambie, A. Miremadi, S. E. Pinder et al., “Prognostic
signiﬁcance of BRCA1 expression in sporadic breast carcino-
mas,” Journal of Pathology, vol. 200, no. 2, pp. 207–213, 2003.
[106] Q. Yang, T. Sakurai, I. Mori et al., “Prognostic signiﬁcance of
BRCA1 expression in Japanese sporadic breast carcinomas,”
Cancer, vol. 92, no. 1, pp. 54–60, 2001.
[107] M.Taron,R.Rosell,E.Felipetal.,“BRCA1mRNAexpression
levels as an indicator of chemoresistance in lung cancer,”
Human Molecular Genetics, vol. 13, no. 20, pp. 2443–2449,
2004.
[108] M. Margeli, B. Cirauqui, E. Castella et al., “The prognostic
value of BRCA1 mRNA expression levels following neoadju-
vant chemotherapy in breast cancer,” PLoS ONE, vol. 5, no.
3, 2010.
[109] J. E. Quinn, C. R. James, G. E. Stewart et al., “BRCA1 mRNA
expressionlevelspredictforoverallsurvivalinovariancancer
after chemotherapy,” ClinicalCancerResearch,vol.13, no.24,
pp. 7413–7420, 2007.
[110] J. I. Weberpals, D. Tu, J. A. Squire et al., “Breast cancer
1 (BRCA1) protein expression as a prognostic marker in
sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16
correlative study 5,” Annals of Oncology. In press.
[111] T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R. A.
Sharma,“DNArepairpathwaysastargetsforcancertherapy,”
Nature Reviews Cancer, vol. 8, no. 3, pp. 193–204, 2008.
[112] P. C. Fong, D. S. Boss, T. A. Yap et al., “Inhibition of
poly(ADP-ribose) polymerase in tumors from BRCA muta-
tion carriers,” New England Journal of Medicine, vol. 361, no.
2, pp. 123–134, 2009.
[113] A. Tutt, M. Robson, J. E. Garber et al., “Oral poly(ADP-
ribose) polymerase inhibitor olaparib in patients with
BRCA1 or BRCA2 mutations and advanced breast cancer: a
proof-of-concept trial,” The Lancet, vol. 376, no. 9737, pp.
235–244, 2010.